Featured projects

Patient-derived liver biopsy-organoids for personalized medicine in NAFLD (Non-Alcoholic Fatty Liver Disease): towards real time assessment of drug response (B-ORG)

Principal investigator: Pau Sancho Bru.
Funder: Ministerio de Ciencia e Innovación.

Code: IBEC_ProyectCompl22.

Duration: 13/04/2023 - 31/12/2024
Dissecting the role of the 14q32 region in hepatoblastoma Hblast14

Principal investigator: Pau Sancho Bru.
Funder: Worldwide Cancer Research.

Code: INT_WWCR_22.

Duration: 01/04/2023 - 31/03/2026
Off the shelf hepatic stellate cells for liver disease modeling and drug screening

Principal investigator: Pau Sancho Bru.
Funder: Instituto de Salud Carlos III.

Code: FIS_DTS22.

Duration: 01/01/2023 - 31/12/2025
Precision medicine for hepatoblastoma: identification of novel therapies and predictive biomarkers using a unique EU biorepository (PMed4HB)

Principal investigator: Pau Sancho Bru.
Funder: Asociación Española Contra el Cáncer (AECC).

Code: PRYCO223102ARME.

Duration: 01/01/2023 - 01/12/2028
Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH transition to inform early prevention and treatment strategies. (Halt-RONIN)

Principal investigator: Pau Sancho Bru.
Funder: European Commission.

Duration: 01/12/2022 - 30/11/2026
Mechanisms of impaired liver regeneration in alcoholic liver disease: drivers and therapeutic targets

Principal investigator: Pau Sancho Bru.
Funder: Instituto de Salud Carlos III.

Code: PI20/00765.

Duration: 01/01/2021 - 31/12/2023
Understanding hepatoblastoma to design new personalized treatments (HB-Project)

Principal investigator: Pau Sancho Bru.
Funder: Asociación Española Contra el Cáncer (AECC)..

Code: AECC-Proyectos19.

Duration: 01/12/2019 - 30/11/2022
Liver-enriched Transcription Factors as Prognostic Markers and Therapeutic Targets in Alcoholic Hepatitis (LiverTF)

Principal investigator: Pau Sancho Bru.
Funder: National Institutes of Health (NIH).

Code: 5U01AA026972.

Duration: 22/09/2018 - 30/06/2020

The research of this group can be carried out thanks to the funders.

Featured projects

Patient-derived liver biopsy-organoids for personalized medicine in NAFLD (Non-Alcoholic Fatty Liver Disease): towards real time assessment of drug response (B-ORG)

Dissecting the role of the 14q32 region in hepatoblastoma Hblast14

Off the shelf hepatic stellate cells for liver disease modeling and drug screening

Precision medicine for hepatoblastoma: identification of novel therapies and predictive biomarkers using a unique EU biorepository (PMed4HB)

Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH transition to inform early prevention and treatment strategies. (Halt-RONIN)

Mechanisms of impaired liver regeneration in alcoholic liver disease: drivers and therapeutic targets

Understanding hepatoblastoma to design new personalized treatments (HB-Project)

Liver-enriched Transcription Factors as Prognostic Markers and Therapeutic Targets in Alcoholic Hepatitis (LiverTF)

Major founders